The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | Artificial intelligence in myeloma
Jill Corre, PharmD, PhD, of L’Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France, discusses machine learning, a branch of artificial intelligence, and its prospects in the field of myeloma treatment and diagnosis. Dr Corre explains that adopting machine learning may be a crucial step in the advancement for myeloma, such as for the identification of high-risk patients with complex disease. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
